Assessing Phase 3 ASCENT-03 Trial Results for Trodelvy in First-line Metastatic Triple-Negative Breast Cancer

Scheduled for:Dec 28, 2025 7:00 PM EDT

Call Duration:30 minutes

Desired Expert

An oncologist with expertise in breast cancer, particularly in triple-negative subtypes. The expert should have experience with antibody-drug conjugates (ADCs), clinical trial design and interpretation, and managing early-line treatment decisions in advanced mTNBC populations.

Interview Goal

The interview aims to evaluate the recently announced topline results from Gilead's Phase 3 ASCENT-03 trial, where Trodelvy (sacituzumab govitecan) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) over standard chemotherapy in patients with first-line metastatic triple-negative breast cancer (mTNBC) not eligible for immune checkpoint inhibitors. The conversation will explore clinical relevance, safety data, treatment implications, and positioning of Trodelvy in a high-unmet-need population.

Slingshot Insights Explained

Expert research benefits investors by giving them timely access to unbiased real world perspectives on highly specialized topics. Slingshot Insights' crowdfunded model makes this access available at a fraction of the cost of other expert networks.